Document Detail

Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
MedLine Citation:
PMID:  20046162     Owner:  NLM     Status:  MEDLINE    
The importance of renin-angiotensin aldosterone system (RAAS) in cardiovascular and renal diseases has long ago been recognized. However despite the availability of many effective drugs, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, RAAS blockade is incomplete in several patients with consequent uncontrolled high blood pressure and not efficacy cardiovascular and renal protection. Aliskiren is a new renin inhibitor that block the RAAS at its origin. Recent studies suggest that Aliskiren reduces blood pressure, inhibits plasma renin activity and attenuates renal damage in diabetic patients with nephropathy. This review summarized the results of the more important studies performed in hypertensive and diabetic patients in which Aliskiren showed to be a safe and effective antihypertensive agent that can be used in monotherapy or in combination with other drugs to provide additional options to improve blood pressure control.
M Dalla Vestra; N Simioni; A Masiero
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Minerva endocrinologica     Volume:  34     ISSN:  0391-1977     ISO Abbreviation:  Minerva Endocrinol.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2010-01-04     Completed Date:  2010-05-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406505     Medline TA:  Minerva Endocrinol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  333-8     Citation Subset:  IM    
Cittadella General Hospital, Padua, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / physiology
Amides / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  therapeutic use
Antihypertensive Agents / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Clinical Trials as Topic / statistics & numerical data
Diabetic Nephropathies / drug therapy,  prevention & control
Double-Blind Method
Drug Therapy, Combination
Fumarates / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Hypertension / drug therapy
Randomized Controlled Trials as Topic / statistics & numerical data
Renin / antagonists & inhibitors*
Renin-Angiotensin System / drug effects*,  physiology
Reg. No./Substance:
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; 52-39-1/Aldosterone; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Male osteoporosis.
Next Document:  Seroprevalence of human brucellosis among the population at risk in rural area.